Literature DB >> 3159585

HLA class II restriction governing cell cooperation between antigen-specific helper T lymphocytes, B lymphocytes and monocytes for in vitro antibody production to influenza virus.

A Fischer, G Sterkers, D Charron, A Durandy.   

Abstract

To study HLA class II compatibility requirement for in vitro antibody production to influenza virus, semipurified T lymphocytes, B lymphocytes and monocytes from HLA-typed responder donors were used. The presence of the three subpopulations was required for antibody production while a mixture of only two of those was ineffective. When using fresh T lymphocytes which exert an allogeneic suppressive effect and may also exhibit allogeneic helper activity, it was not possible to conclude an HLA class II-linked restriction of T-B cell cooperation although there was a suggestion of it. However, a grown H3 hemagglutinin-specific T cell line (L2), previously shown to be restricted by HLA-DR molecule (DR1) for interaction with antigen-presenting cells and devoid of allogeneic reactivity, exerts an HLA class II-restricted helper activity. This was demonstrated by various combinations of HLA-DR semi-compatible or incompatible B lymphocytes and/or monocytes with L2 T cells. The restriction element was identified as an HLA-DR determined since HLA-DC-compatible, HLA-DR-incompatible B lymphocytes were not helped by L2 T cells. In addition, monoclonal anti-HLA-DR but not anti-HLA-DC antibodies directed to the relevant specificity did inhibit the antigen-specific helper activity. We present evidence that not only T monocyte but also T-B and/or T-B-monocyte interactions are HLA class II restricted.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159585     DOI: 10.1002/eji.1830150617

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Limiting dilution analysis of specific in vitro anti-herpes simplex virus antibody production by human lymphocytes.

Authors:  M Yasukawa; Y Kobayashi
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Activation of genetically major histocompatibility complex (MHC) class II-deficient B lymphocytes.

Authors:  A Durandy; M Mangeney; C Griscelli; M Forveille; F Le Deist; A Fischer
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

3.  Specific binding of antigen onto human T lymphocytes.

Authors:  A Durandy; A Fischer; D Charron; C Griscelli
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

4.  The expression of class II MHC gene products by fallopian tube epithelium in pregnancy and throughout the menstrual cycle.

Authors:  J N Bulmer; U Earl
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

5.  Expression of class II MHC gene products by macrophages in human uteroplacental tissue.

Authors:  J N Bulmer; L Morrison; J C Smith
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

6.  HLA-D subregion expression by thyroid epithelium in autoimmune thyroid diseases and induced in vitro.

Authors:  I Todd; R Pujol-Borrell; B A Abdul-Karim; L J Hammond; M Feldmann; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

7.  Proliferative T-cell response to glycoprotein B of the human herpes viruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity.

Authors:  W L Chan; M L Tizard; L Faulkner
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

8.  Deficiency of the adhesive protein complex lymphocyte function antigen 1, complement receptor type 3, glycoprotein p150,95 in a girl with recurrent bacterial infections. Effects on phagocytic cells and lymphocyte functions.

Authors:  A Fischer; R Seger; A Durandy; B Grospierre; J L Virelizier; F Le Deist; C Griscelli; E Fischer; M Kazatchkine; M C Bohler
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  Mannan-specific and mannan-induced T-cell suppressive activity in patients with chronic mucocutaneous candidiasis.

Authors:  A Durandy; A Fischer; F Le Deist; E Drouhet; C Griscelli
Journal:  J Clin Immunol       Date:  1987-09       Impact factor: 8.317

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.